Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,400.96
(
-0.16%
)
US TECH 100
28,206.80
(
-1.14%
)
Dow Jones
49,760.56
(
0.11%
)
Brent Oil
104.63
(
-1.07%
)
Bitcoin
81,036.49
(
0.68%
)
News Focus
News Focus
Post# of 347009
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 84
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: Carboat post# 279582

Saturday, 11/26/2016 12:06:54 AM

Saturday, November 26, 2016 12:06:54 AM

Post# of 347009
Peregrine Pharmaceuticals Buy Low then Sell High

We are at the buy low stage and CEO Steve King doing a great job on the science side and the wall street side will catch up once a deal is announced and that could be any day now.

Memorial Sloan Kettering Dr. Jedd Wolchok just validated PS Targeting and still have AstraZeneca and Merck trials with PS Targeting

Biomarkers are all the hype and PS Targeting biomarkers are coming... actually in December just 2 weeks ago

Has anyone heard about the exosome test kits?

Avid manufacturing expansions?

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote